Analyst Marc Goodman of Leerink Partners reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman gave his rating based on several factors related to Biohaven Ltd.’s potential in addressing spinocerebellar ataxia (SCA). The company is on the brink of a significant milestone with the anticipated FDA decision regarding the New Drug Application (NDA) for troriluzole in SCA. This development follows positive data outcomes showing a 50-70% slowing in disease progression, as evidenced by real-world data from study BHV4157-206-RWE.
Goodman’s optimism is also fueled by the regulatory landscape, where there is a precedent for NDA approval in similar cases, combined with the high unmet medical need due to the lack of approved treatments for SCA. The stock’s previous positive reaction, a 20% increase, suggests investor confidence and a positive market outlook should the FDA accept the NDA. In such a scenario, Goodman anticipates further stock appreciation, while acknowledging the potential risk should the FDA issue a refusal to file. This risk-reward balance underpins his Buy rating.